Home > Boards > US OTC > Miscellaneous > Therapeutic Solutions International, Inc. (TSOI)

TSOI News History 5/1/18 - 1/22/19

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
centsability4me Member Profile
Member Level 
Followed By 34
Posts 3,382
Boards Moderated 3
Alias Born 06/17/13
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 12/12/2019 12:13:37 PM
Therapeutic Solutions International Enters into Multi-Million Dollar Master Sales Agreement with Tiva Bio InvestorsHub NewsWire - 12/12/2019 9:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/20/2019 12:56:29 PM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) Edgar (US Regulatory) - 11/14/2019 3:35:10 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/12/2019 4:05:22 PM
Therapeutics Solutions International Signs Agreement with Beijing Regenesis Biotechnology InvestorsHub NewsWire - 11/11/2019 9:00:00 AM
Therapeutics Solutions International Reports Augmentation of Rejuvenating Activity of Cord Blood Plasma by Pterostilbene InvestorsHub NewsWire - 11/4/2019 9:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/9/2019 12:59:28 PM
Therapeutic Solutions International Reports NanoStilbene™ Protects the Immune System from Cancer Chemotherapy InvestorsHub NewsWire - 9/9/2019 9:00:00 AM
Feng Lin, MD, Ph.D., Joins Therapeutic Solutions International as Chief Scientific Officer InvestorsHub NewsWire - 9/3/2019 9:00:00 AM
Therapeutic Solutions International, Inc. Reports Revenues Up 850% for Q2 and 850% for 1st 6 months InvestorsHub NewsWire - 8/29/2019 9:00:00 AM
Therapeutic Solutions International Announces Positive Clinical Data Using NanoStilbene™ to Stimulate Immune System InvestorsHub NewsWire - 8/26/2019 9:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/16/2019 4:28:47 PM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) Edgar (US Regulatory) - 8/13/2019 1:46:36 PM
Therapeutic Solutions International Collaborates with Right to Try Foundation on Novel Means of Protecting Patients InvestorsHub NewsWire - 8/5/2019 9:00:00 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 7/30/2019 4:44:49 PM
NanoStilbene™ Nutraceutical Shown to Increase Ability of Cyclophosphamide Chemotherapy to Suppress Cancer InvestorsHub NewsWire - 7/29/2019 9:00:00 AM
Therapeutic Solutions International Reports its NanoStilbene™ Nutraceutical Product Enhances Efficacy of FDA Cleared Ca... InvestorsHub NewsWire - 7/22/2019 9:00:00 AM
Therapeutic Solutions International adds Nano Cannabidiol to NanoMyros for Inhibition of Microvesicle and Exosome Release InvestorsHub NewsWire - 7/15/2019 9:00:00 AM
Therapeutic Solutions International Develops Adjuvant Technology to Enhance Prostate Cancer Suppressing Properties of InvestorsHub NewsWire - 7/11/2019 9:00:00 AM
Therapeutic Solutions International Develops Glucoraphanin + NanoStilbene Encapsulated product InvestorsHub NewsWire - 7/8/2019 9:00:00 AM
Therapeutic Solutions International Obtains Exclusive License for Patented Clinical Stage Adult Stem Cell for Treatment of InvestorsHub NewsWire - 7/1/2019 9:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/19/2019 11:12:46 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/20/2019 11:18:31 AM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) Edgar (US Regulatory) - 5/14/2019 11:22:33 AM
centsability4me Member Level  Wednesday, 01/23/19 06:19:26 AM
Re: None
Post # of 13041 
TSOI News History 5/1/18 - 1/22/19

NEWS 1/22/19

Therapeutic Solutions International Continues to Expand Chronic Traumatic Encephalopathy Intellectual Property Portfolio
Patent for Prevention and Reversion of CTE using "Educated" Monocytes and Progenitor Cells

NEWS 1/14/19

Therapeutic Solutions International Announces Preliminary Data for Immune Stimulation in Advanced Cancer Patients by Commercially Available Product
NanoStilbene Shown to Enhance Anticancer Immunity in Cancer Patients
through Modulation of Inflammatory Mediators

NEWS 1/9/19

Therapeutic Solutions International Continues to Expand Chronic Traumatic Encephalopathy Intellectual Property Portfolio
Patent filed for Autologous Neurogenic Cells in Professional Athletes at Risk of CTE

NEWS 12/31/18

Therapeutic Solutions International CEO Issues Shareholder Letter

NEWS 12/10/18

Therapeutic Solutions International Signs Agreement for Licensing JadiCell's Universal Donor Adult Stem Cell Product

NEWS 12/6/18


Therapeutic Solutions International Expands Chronic Traumatic Encephalopathy Intellectual Property Portfolio
New Data Demonstrates Ability of Immune System to Alter Football Related Brain Injuries

NEWS 10/25/18


Therapeutic Solutions International Announces CTE Optimized NeuroStilbene Formulation

NEWS 9/25/18


Therapeutic Solutions International Files Patent on Clinical Data Demonstrating Reduction of Inflammatory Cytokines Using NanoStilbeneTM

NEWS 9/19/2018


Therapeutic Solutions International Collaborates with Internationally Renowned Neurologist and NFL Charger Hall of Famer to Develop New Intellectual Property for Treatment of Chronic Traumatic Encephalopathy
Company Files Patent and Generates Proof of Concept Data using NeuroStilbene for Prevention of Football Associated Brain Damage

NEWS 9/4/18


Therapeutic Solutions International Completes Phase 1 Clinical Trial in Advanced Cancer Patients for Right to Try Access
of its StemVacs Product for American Cancer Patients

NEWS 8/22/18


Therapeutic Solutions International Recruits NFL Chargers Hall of Famer Wes Chandler to Lead NeuroStilbene for Chronic Traumatic Encephalopathy in Football Players
Company to Advance NeuroStilbene Product for High-Performance Athletes Susceptible to Head Injuries

NEWS 8/13/18

Therapeutic Solutions International Reports Synergistic Enhancement of Ozone Therapy Efficacy in Prostate, Breast and Ovarian Cancer Cells by Pterostilbene
Clinical Stage Cancer Immunotherapy Biotechnology Company Files Patent Expanding Uses of its Pterostilbene Based Product Pipeline

NEWS 8/6/18


Therapeutic Solutions International Develops Microemulsion Formulation of Alpha Lipoic Acid for Intranasal Delivery

Company Expands Product Pipeline in Neurodegenerative Arena

NEWS 7/23/18

Therapeutic Solutions International Recruits Internationally Recognized Cancer Immunotherapy Pioneer Dr. Francesco Marincola to Accelerate StemVacs and NanoStilbene Clinical Development
Company Focuses on Non-Toxic Therapies Using Immune System
to Selectively Kill Cancer Cells through Immunotherapy

NEWS 7/16/18

Therapeutic Solutions International, Inc., Releases Intranasal Formulation of Pterostilbene for Rapid Access to Blood-Brain Barrier
Company Expands its Pterostilbene Based Portfolio into Brain Cancers

NEWS 7/9/18


Therapeutic Solutions International, Inc., Appoints Juergen Winkler, MD, ABIHM to Scientific Advisory Board
Pioneer of Functional Medicine Teams Up with Clinical Stage Biotechnology Company in Commercialization of Non-Toxic Immunotherapy

NEWS 7/2/18


Therapeutic Solutions International Announces Clinical Proof of Concept of Nanoparticle Pterostilbene Formulation: NanoStilbene™
Early Clinical Trial Data Supports Enhanced Biodistribution of NanoStilbene™ Compared to Standard Pterostilbene When Orally Administered

NEWS 6/25/18

Therapeutic Solutions International Releases "IsoStilbene" Injectable Formulation of Pterostilbene Under Granted Patent for Augmentation of Immunotherapy and Targeting of Cancer Stem Cells . IsoStilbene to be Included in Pan American Cancer Treatment Center Protocols

NEWS 6/18/18


Therapeutic Solutions International Announces the Appointment of
James Veltmeyer, MD as Chief Medical Officer

NEWS 6/11/18


Therapeutic Solutions International Expands Adoptive Immunotherapy Portfolio by Incorporation of "Universal Cancer Antigen" into StemVacs Dendritic Cell Platform



NEWS 6/6/18

Therapeutic Solutions International Announces Licensing of Additional Technologies to
Pan American Cancer Treatment Center

Patent Title: Targeting the Tumor Microenvironment through Nutraceutical Based Immunoadjuvants : Cancer Metabolic DeTox
Patent Title: Methods of Re-Activating Dormant Memory Cells with Anticancer Activity : MemoryMune
Patent Title: Stimulation of Immunity to Tumor Stem Cell Specific Proteins by Peptide Immunization : StemVacs
Patent Title:Augmentation of Anti-Tumor Immunity by Mifepristone and Analogues Thereof : LymphoBoost
Patent Title: Activated Leukocyte Extract for Repair of Innate Immunity in Cancer Patients : innaMune

Pan Am Cancer Treatment Center
Telephone: (619) 735-9581
Diego Rivera #2339 suite 108
Zona Rio, Tijuana B.C. 22010
Pan Am Cancer Treatment Center Intoductory video :

NEWS 5/31/18


Therapeutic Solutions International to Provide Patients Access to StemVacs Cancer Immunotherapy through Newly Passed Right to Try Law

NEWS 5/21/18


Therapeutic Solutions International Releases "DermalStilbene" a Topical Formulation of Pterostilbene

NEWS 5/15/18


Therapeutic Solutions International, Inc., to Initiate Clinical Trial of Patented Cancer Immunotherapy Adjuvant Nanostilbene

NEWS 5/9/18

Therapeutic Solutions International, Inc., Announces the Appointment of Nassir Azimi, MD, to Science Board
Company to Iniate Investigational Cardiovascular Study with Dr. Azimi and Nanostilbene

NEWS 5/1/18

Therapeutic Solutions International Launches Multi-Protocol Cancer Immunotherapy Clinical Trial with Pan Am Cancer Treatment Center
Company Aims to Leverage Transfer Factor Pulsed Autologous Dendritic Cells on StemVacs Platform with
Patented Augmenter of Cancer Immunotherapy NanoStilbene

Pan Am Cancer Treatment Centers website

TSOI Patent covering NanoStilbene

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist